ArticleJournal of fluorescence2025
Green Assessment of Sensitive Spectrofluorimetric Methods for Simultaneous Estimation of Formoterol Fumarate and Fluticasone Propionate Using a Micelle-Mediated Approach.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Highly sensitive spectrofluorimetric methods were developed for the quantitative estimation of formoterol fumarate dihydrate (FFD) and fluticasone propionate (FP) in both authentic raw materials and marketed dosage forms using a micellar-enhanced spectrofluorimetric approach. The proposed methods are based on the determination of FP in the presence of FFD using the first derivative emission spectrofluorimetry. The peak amplitude of the emission spectra of the formed micellar fluorescence was measured at 465 nm after excitation at 236 nm (λ max of FP).The second method quantifies FFD in the presence of FP using second derivative emission spectrofluorimetry. This method measures the peak amplitude of the emission spectra of the formed micelle at 283 nm, where there is no interference from FP, following excitation at 214 nm. In these methods, the emission spectra of the target drugs are measured after micellar formation, with excitation wavelengths at 214 nm for FFD and 236 nm for FP. The fluorescence intensity was enhanced using β-cyclodextrin as a micellar system after optimizing parameters affecting native fluorescence, such as diluting solvents, surfactants, and varying concentrations of β-cyclodextrin. A linear relationship was observed between the fluorescence intensity and concentration for FP over the range of 50-100 ng/mL and for FFD over the range of 30-700 ng/mL. The developed methods are simple, sensitive, non-extractive, economical, and suitable for routine analysis of FFD and FP in their raw materials and combined marketed dosage forms. The proposed techniques were carefully validated for linearity, accuracy, precision, and specificity according to the International Council for Harmonization (ICH) guidelines, demonstrating high sensitivity with lower limits of detection and quantitation. Additionally, the analytical greenness of the suggested procedures was assessed using the Analytical Greenness Metric Approach (AGREE), the Red-Green-Blue model, and the Green Procedure Analytical Index (GAPI).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.